CLDN18 and gastric cancer: Ungureanu et al. showed that specific binding of zolbetuximab to the first extracellular domain of CLDN18 splice variant 2 (CLDN18.2) with high affinity can induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity leading to the destruction of gastric cancer cells that express CLDN18.2.